Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Control of cell death is frequently disrupted in cancer resulting in overgrowth of tumour cells. Caspase-8 is a key enzyme involved in controlling cell death. This study examines the importance of caspase-8 in oral cancer.
Control of cell death is frequently disrupted in cancer resulting in overgrowth of tumour cells. The caspase family of enzymes are the key performers of controlled cell death and caspase-8 is frequently mutated in oral cancer. This study will perform DNA sequencing to determine if the gene is wild-type (not mutated). The abundance of inactive (uncleaved) and active (cleaved) caspase-8 will be determined. The levels of the proteins that caspase-8 interacts with (including caspase-3) will be determined. Results will be correlated with tumour stage, patient outcome and the presence of immune cells and other microscopic features. This will improve the understanding of the importance of caspase-8 in oral cancer.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| There is no intervention. | Other | There is no intervention. This is a retrospective study analysing archived tumour samples. |
| Measure | Description | Time Frame |
|---|---|---|
| Caspase-8 activity in oral cancer and its impact on disease progression | Molecular analysis of caspase-8 activity will be undertaken and correlated with tumour features and outcome. | Up to 3 years |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Archived oral cancer tissue specimens within this single institute.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Robert Kennedy, BSc PhD BDS | Contact | 07815501088 | robert.kennedy@kcl.ac.uk |
| Name | Affiliation | Role |
|---|---|---|
| Robert Kennedy, BSc PhD BDS | KCL | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Robert Kennedy | Recruiting | London | SE19RT | United Kingdom |
No patient identifiable data is stored
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | May 4, 2023 | |
| Reset | Jan 23, 2024 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| May 4, 2023 | Jan 23, 2024 |
| ID | Term |
|---|---|
| D009062 | Mouth Neoplasms |
| ID | Term |
|---|---|
| D006258 | Head and Neck Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D009059 | Mouth Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| D009057 |
| Stomatognathic Diseases |